CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,279 enrolled
Drug / intervention
lorlatinib +17 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05834348
NCT05834348N/ACompleted

Drug Treatment Patterns and Effects for Metastatic Non-small Cell Lung Cancer Patients In NORway (DELINOR)

Pfizer·observational·Posted Apr 28, 2023·Updated Mar 30, 2025

In Brief

An observational study evaluating lorlatinib, crizotinib, and 16 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 5,279 participants across 1 site.

Detailed Summary

The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. Metastasis is when the cancer cells spread to other parts of the body. This study includes patient's data from the database who: * Are 18 years of age or older. * Are confirmed to have metastatic non-small cell lung cancer between 01 January 2009 and 31 December 2022. The study is based on data collection from 3 national health registries: * The Cancer Registry of Norway (CRN), * The Norwegian Patient Registry (NPR), * The Norwegian Drug Registry (NDR). Data from these registries will be linked at an individual patient level to create a single, unified dataset. The information collected includes: Diagnosis, cancer stage at diagnosis, date of diagnosis, birth year, type of medicinal treatment, date of treatment start and end, treating hospital, age, gender, etc.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesNorway
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedApr 28, 2023
Enrollment StartJun 23, 2023
Primary CompletionJan 23, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.2 years ago

Interventions

lorlatinibdrug

As provided in real world practice

crizotinibdrug

As provided in real world practice

brigatinibdrug

As provided in real world practice

ceritinibdrug

As provided in real world practice

alectinibdrug

As provided in real world practice

atezolizumabdrug

As provided in real world practice

bevacizumabdrug

As provided in real world practice

paclitaxeldrug

As provided in real world practice

carboplatindrug

As provided in real world practice

docetaxeldrug

As provided in real world practice

erlotinibdrug

As provided in real world practice

gefitinibdrug

As provided in real world practice

afatinibdrug

As provided in real world practice

dacomitinibdrug

As provided in real world practice

osimertinibdrug

As provided in real world practice

pembrolizumabdrug

As provided in real world practice

nivolumabdrug

As provided in real world practice

entrectinibdrug

As provided in real world practice